Patents Represented by Attorney, Agent or Law Firm Mark J. Stewart
  • Humanized antibodies
    Patent number: 7320790
    Abstract: Humanized forms of mouse antibody 10D5 that retain the binding properties of mouse 10D5 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Paul Robert Hinton, Maximiliano J. Vasquez
  • Humanized antibodies that sequester abeta peptide
    Patent number: 7195761
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13–28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: March 27, 2007
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6703365
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: March 9, 2004
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
    Patent number: 6660716
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: December 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Vignati Louis
  • Use of GLP-1 analogs and derivative adminstered peripherally in regulation of obesity
    Patent number: 6583111
    Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: June 24, 2003
    Assignee: Eli Lilly and Company
    Inventors: Richard DiMarchi, Suad Efendic
  • Protein formulations
    Patent number: 6573237
    Abstract: The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic preservative, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: June 3, 2003
    Assignee: Eli Lilly and Company
    Inventor: Vincent Joseph Rinella, Jr.
  • Glucagon-like peptide-1 crystals
    Patent number: 6555521
    Abstract: The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: April 29, 2003
    Assignee: Eli Lilly and Company
    Inventors: Ronald Norbert Hermeling, James Arthur Hoffmann, Chakravarthy Narasimhan
  • Stable insulin formulations
    Patent number: 6551992
    Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: April 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Michael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun
  • Protein formulations
    Patent number: 6440930
    Abstract: The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic preservative, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 27, 2002
    Assignee: Eli Lilly and Company
    Inventor: Vincent Joseph Rinella, Jr.
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6410513
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: June 25, 2002
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffman
  • DNA encoding Rhesus ob protein
    Patent number: 6395509
    Abstract: The invention includes isolated nucleic acid molecules encoding a Rhesus ob gene product that regulates obesity in mammals. A preferred embodiment consisting of a native DNA sequence is disclosed, as are vectors and methods for expressing the Rhesus ob gene product.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: May 28, 2002
    Assignee: Eli Lilly and Company
    Inventors: Margret B. Basinski, Brigitte E. Schoner
  • Glucagon-like insulinotropic peptides, compositions and methods
    Patent number: 6388053
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: May 14, 2002
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann
  • Glucagon-like peptide-1 crystals
    Patent number: 6380357
    Abstract: The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: April 30, 2002
    Assignee: Eli Lilly and Company
    Inventors: Ronald Norbert Hermeling, James Arthur Hoffmann, Chakravarthy Narasimhan
  • GLP-1 formulations
    Patent number: 6358924
    Abstract: Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other GLP-1 treated conditions.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: March 19, 2002
    Assignee: Eli Lilly and Company
    Inventor: James Arthur Hoffmann
  • Use of GLP-1 or analogs in treatment of myocardial infarction
    Patent number: 6277819
    Abstract: This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: August 21, 2001
    Assignee: Eli Lilly and Company
    Inventor: Suad Efendic
  • Stable insulin formulations
    Patent number: 6034054
    Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: March 7, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun
  • Bovine dipeptidylaminopeptidase 1
    Patent number: 6027911
    Abstract: The present invention provides the cDNA sequence encoding bovine dipeptidylaminopeptidase 1. The invention demonstrates that bovine DAP 1 coded by a single cDNA. The mature protein is derived from a single polypeptide consisting of a signal peptide, and a major polypeptide which is processed to generate the a subunit, b subunit and g subunit.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: February 22, 2000
    Assignee: Eli Lilly and Company
    Inventors: Christopher Carl Frye, Charles Lee Hershberger, Haichao Zhang
  • Monomeric insulin analog formulations
    Patent number: 5952297
    Abstract: The present invention discloses various parenteral pharmaceutical formulations having a protracted effect, which comprise: a sterile aqueous suspension of about 20 U/mL to about 500 U/mL insulin analog, about 5 mg/mL to about 10 mg/mL sodium chloride, about 0.2 to about 2.0 mg/mL physiologically acceptable buffer, a zinc ion content of about 0.07 mg/mL to about 0.1 mg/mL, and a physiologically acceptable preservative at a pH of about 6.5 to about 7.8; such that less than 5% of the analog present in the suspension is in the dissolved state.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: September 14, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael R. De Felippis, Bruce H. Frank
  • Monofunctional glycosyltransferase gene of Staphylococcus aureus
    Patent number: 5922540
    Abstract: The invention provides isolated nucleic acid compounds encoding a novel MTG of Staphylococcus aureus. Also provided are vectors and transformed heterologous host cells for expressing the MTG and a method for identifying compounds that bind and/or inhibit the enzymatic activity of the MTG.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: July 13, 1999
    Assignee: Eli Lilly and Company
    Inventors: Jo Ann Hoskins, Stanley R. Jaskunas, Jr., Robert B. Peery, Paul L. Skatrud